Biomarker-guided treatment study for older adults with AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (at least 60 at diagnosis for most parts of the trial).
- Your AML matches one of the allowed categories (new/untreated, relapsed, or refractory) and—if required—has the specific gene changes the sub-study needs.
- You can understand the study and sign written consent (and be able to attend follow-up visits).
- Your overall body function/labs are within safe ranges for the sub-study (liver, kidney, and blood counts).
- You do NOT have certain AML subtypes or urgent complications (like acute promyelocytic leukemia or needing immediate treatment for “leukostasis”).
- You have no major medical problems that would make treatment unsafe or confusing (and certain infections like uncontrolled HIV/hepatitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Hear when a new Previously Untreated Relapsed Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.